The real-world comparative effectiveness of covalent BTKis in R/R MCL 

Tycel Phillips, MD, City of Hope, Duarte, CA, discusses the real-world comparative effectiveness of covalent BTK inhibitors (BTKis) among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). While the efficacy of these BTKis has traditionally been considered equivalent, second-generation BTKis acalabrutinib and zanubrutinib show an improved toxicity profile compared to the first-generation ibrutinib. Real-world data indicate that zanubrutinib improves overall response rate (ORR) and duration of response (DOR) compared to ibrutinib, possibly due to fewer treatment discontinuations from toxicity. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.